Cognitive ImpairmentSINGERNCT05007353
The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) Study
A study testing Structured Lifestyle Intervention and Self-Guided Intervention in people with Cognitive Impairment and Alzheimer Disease, run by National University of Singapore at 3 sites in Singapore.
Trial summary
A study in Finland found that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. Read more about this study
- Who is it for?
- Ages 60 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Impairment, Alzheimer Disease, Vascular Cognitive Impairment
- What is being tested?
- Structured Lifestyle Intervention and Self-Guided Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,212 participants
- Where
- 3 sitesSingapore
- Study dates
- 23 Aug 2021to 29 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 60-80 years
- Able to understand English/Chinese
- Risk of dementia: Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) dementia risk score ≥6 indicating the presence of modifiable risk factors Modifiable lifestyle factors (fulfilling at least one of the following LIBRA index for diet, cognitive activity, physical activity)
- Cognitive performance at the mean level or slightly lower than expected for age (MoCA ≥18, ≤27)
- No plans to travel outside of Singapore for an extended period of time over the course of the study
- Free of physical disabilities that preclude participation in the study
- Willing to complete all study-related activities for 24 months
- Willing to be randomized to either lifestyle intervention group
Who cannot join
- malignant diseases
- dementia
- major depression
- symptomatic cardiovascular disease
- revascularisation within 1 year
- severe loss of vision, hearing or communicative ability
- other conditions inhibiting from safe engagement in the prescribed intervention and other conditions preventing cooperation, as judged by the study physician
Trial locations and contacts
3 sites in 1 country.
Singapore3 sites
National University Hospital
Singapore, Singapore, 117600
National University of Singapore, Yong Loo Lin School of Medicine
Singapore, Singapore, 117600
National Neuroscience Institute @ Tan Tock Seng Campus (NNI @ TTSH campus)
Singapore, Singapore, 308433
About this study
Official title: The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) Study, Biomarker and Health Service Research Analyses
A study in Finland found that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. The SINGER study is a 2-year randomized controlled trial that aims to test the efficacy and safety of these lifestyle changes, including diet and cardiovascular risk factor management, cognitive and physical exercises, in delaying cognitive decline in older adults at risk of dementia.
Read the detailed description
Results from a population-based 2-year clinical trial, the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), demonstrated that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. Currently, no pharmacological treatment options that can rival these effects. Thus, there is an urgent need to test the generalizability, adaptability, and sustainability of these findings in Singaporean populations. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. Hence, the next step was to conduct a larger scale SINGER trial to determine the efficacy of these interventions in Singapore. If the interventions are found to be effective and safe with high applicability and scalability, the study will provide important clinical and public health implications to a rapidly increasing ageing population.
- Conditions
- Cognitive Impairment, Alzheimer Disease, Vascular Cognitive Impairment, Dementia, Brain Diseases, Central Nervous System Diseases
- Being tested
- Structured Lifestyle Intervention, Self-Guided Intervention
- Keywords
- cognitive decline, cognitive impairment, multi-domain lifestyle interventions, dementia, elderly
- Medical subject headings
- Cognitive Dysfunction, Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurocognitive Disorders, Mental Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Structured Lifestyle InterventionBehavioural
Also called SLI
Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
Self-Guided InterventionBehavioural
Also called SGI
In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
| Study group | Role | What they receive |
|---|---|---|
| Structured Lifestyle Intervention | Experimental | Structured lifestyle modification program developed for participants targeting diet, physical exercise, cognitive training, and social stimulation. Receives: Behavioral: Structured Lifestyle Intervention |
| Self-Guided Intervention | Experimental | General health information provided to participants. Receives: Behavioral: Self-Guided Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Global Cognition
Global cognition measured using the modified Neuropsychological Test Battery (mNTB) that includes: Visual Paired Associates, Logical Memory Recall of the Wechsler Memory Scale-Revised, Rey Auditory Verbal Learning, Digit Span, Word and Category Fluency test, Trail Making Test, Letter Digit Substitution test.
Measured: Up to 2 years
Secondary outcomes (23)
Episodic Memory
Episodic memory measured using mNTB subtests: Visual paired associates tests, Logical Memory immediate and delayed recall of the Wechsler Memory Scale-Revised, Rey Auditory Verbal Learning test.
Measured: Up to 2 years
Executive Function
Executive function measured using mNTB subtests: Digit Span, Word and Category Fluency test, Trail Making Test Part B.
Measured: Up to 2 years
Processing Speed
Processing speed measured using mNTB subtests: Letter Digit Substitution test and Trail-Making Test Part A.
Measured: Up to 2 years
Clinical Dementia Rating-Sum of Boxes (CDR-SB)
The Clinical Dementia Rating-Sum of Boxes (CDR-SB) is scored from 0 to 18. Higher scores reflect worse performance.
Measured: Up to 2 years
Alzheimer's Disease Cooperative Study Activities of Daily Living-Mild Cognitive Impairment-Activities of Daily Living Inventory (ADCS-MCI-ADL)
The Alzheimer's Disease Cooperative Study Activities of Daily Living-Mild Cognitive Impairment-Activities of Daily Living Inventory (ADCS-MCI-ADL) is scored from 0 to 53. Higher scores reflect better performance.
Measured: Up to 2 years
The Geriatric Depression Scale (GDS)
The Geriatric Depression Scale (GDS) is scored from 0 to 15. Scores of 0-4 are considered normal, 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
Measured: Up to 2 years
Global Physical Activity Questionnaire (GPAQ)
The Global Physical Activity Questionnaire (GPAQ) measures physical activity across 3 domains: work, travel, and recreation, as well as average time per day spent in sedentary behavior. The GPAQ is scored based on a population's mean or median physical activity spent in physical activity or by classifying a certain percentage of a population as 'inactive' or 'insufficiently active'.
Measured: Up to 2 years
Prospective-Retrospective Memory Questionnaire
The Prospective-Retrospective Memory Questionnaire (PRMQ) is measured on a 5-point scale. Higher scores represent greater frequency of memory failures.
Measured: Up to 2 years
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is scored from 0 to 21. Higher scores indicate worse sleep quality.
Measured: Up to 2 years
Leisure-Time Activities Questionnaire
The Leisure-Time Activities Questionnaire measures the frequency of engagement in the following activities: Health activities, Social activities, Productive activities, Fitness activities, Recreational activities, Any cognitively-stimulating activities. Scores are measured on a 3-point scale. Higher scores represent higher frequency of engagement in leisure-time activities.
Measured: Up to 2 years
Physical Performance Test (PPT)
The Physical Performance Test (PPT) is scored from 0 to 36. Higher scores represent better performance.
Measured: Up to 2 years
Quality of Life Questionnaire (15D)
The Quality of Life Questionnaire (15D) has a single index (15D score) on a 0-1 scale, which represents overall HRQoL (0 = being dead, 0.0162 = being unconscious or comatose, 1 = no problems on any dimension = 'full' HRQOL). This is calculated from the health state descriptive system by using a set of population-based preference or utility weights.
Measured: Up to 2 years
36-Item Short Form Survey (SF-36)
The 36-Item Short Form Survey (SF-36) has eight domains. Each domain is scored from 0 to 100. Higher scores represent a more favourable health state.
Measured: Up to 2 years
Resource Use Inventory (RUI)
The Resource Use Inventory (RUI) measures 4 domains: direct medical care, direct nonmedical care, informal care, and subjects' time use. The RUI is filled in based on the frequency and amount of resources used. If none were used, '00' is entered.
Measured: Up to 2 years
Height
Height is measured in metres.
Measured: Up to 2 years
Weight
Weight is measured in kilograms.
Measured: Up to 2 years
Hip and waist circumference
Hip and waist circumference measured in centimetres.
Measured: Up to 2 years
Changes in Blood Pressure
Vascular and metabolic risk factors measured by changes in blood pressure in mmHg. Incident events using serious adverse event reports will also be assessed.
Measured: Up to 2 years
Changes in Lipid Profile
Vascular and metabolic risk factors measured by changes in lipid profile in mmol/L.
Measured: Up to 2 years
Changes in Glucose Regulation
Vascular and metabolic risk factors measured by changes in glucose regulation in mmol/L.
Measured: Up to 2 years
Neuroimaging
Magnetic Resonance Imaging will be used to assess changes in brain structural integrity, grey matter volume loss, white matter microstructure degradation, and increase of cerebrovascular disease markers (CeVD). Vascular polygenic risk scores (PRS) and its association with neurodegeneration, CeVD burden and cognitive decline will be performed.
Measured: Up to 2 years
Blood Biomarkers
Novel and accessible blood markers to monitor AD- and CeVD-associated pathologies will be measured. Plasma concentrations of cardiac markers (High-sensitive cardiac troponin T (hs Troponin T), N-terminal pro b-type natriuretic peptide (NT-proBNP) and Growth/differentiation factor 15 (GDF 15)), and peripheral biomarkers of Aβ, tau and synaptic pathology, oxidative stress, endothelial/cardiovascular injury and degenerative protein modifications (DPMs) damaged proteins will be used.
Measured: Up to 2 years
Retinal Imaging Markers
Multimodal retinal imaging will be used to assess retinal structural, vascular and neuronal changes.
Measured: Baseline only
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Aug 2021
- Study start23 Aug 2021
- Primary completion1 Dec 2025
- Study completion29 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Cognitive ImpairmentStudies of the same condition, open and under way.
- More trials run by National University of SingaporeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 1,212 participants (actual)
Sponsor and investigators
- Lead sponsor
- National University of Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- National Medical Research Council (NMRC), Singapore
- Responsible party
- Principal investigator, Christopher Chen Li-Hsian, National University of Singapore
- Investigators
- Christopher LH Chen, MD, Principal investigator, National University of Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05007353
- Sponsor's protocol ID
- SINGER 2021
- Acronym
- SINGER
- Status last verified
- Jul 2026
- First submitted
- 28 Jul 2021
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Interested collaborators may put in a request.
Publications
Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.
PubMed 25771249Chew KA, Xu X, Siongco P, Villaraza S, Phua AKS, Wong ZX, Chung CY, Tang N, Chew E, Henry CJ, Koo E, Chen C. SINgapore GERiatric intervention study to reduce physical frailty and cognitive decline (SINGER)-pilot: A feasibility study. Alzheimers Dement (N Y). 2021 Mar 15;7(1):e12141. doi: 10.1002/trc2.12141. eCollection 2021.
PubMed 33748399Yap KH, Chen C, Chong EJY, Kandiah N, Kivipelto M, Lai MKP, Maier AB, Matchar DB, Phua AKS, Teo CKL, Xu X, Zhou HJ, Chen CPL. Baseline characteristics of the SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) multidomain dementia prevention randomized controlled trial and insights from the recruitment process. Alzheimers Dement. 2026 Apr;22(4):e71313. doi: 10.1002/alz.71313.
PubMed 41943481Ooi LQR, Orban C, Zhang S, Nichols TE, Tan TWK, Kong R, Marek S, Dosenbach NUF, Laumann TO, Gordon EM, Yap KH, Ji F, Chong JSX, Chen C, An L, Franzmeier N, Roemer-Cassiano SN, Hu Q, Ren J, Liu H, Chopra S, Cocuzza CV, Baker JT, Zhou JH, Bzdok D, Eickhoff SB, Holmes AJ, Yeo BTT; Alzheimer's Disease Neuroimaging Initiative. Longer scans boost prediction and cut costs in brain-wide association studies. Nature. 2025 Aug;644(8077):731-740. doi: 10.1038/s41586-025-09250-1. Epub 2025 Jul 16.
PubMed 40670782
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) Study, Biomarker and Health Service Research Analyses
- ClinicalTrials.gov ID
- NCT05007353
- Acronym / sponsor ID
- SINGER / SINGER 2021
- Conditions
- Cognitive Impairment, Alzheimer Disease, Vascular Cognitive Impairment, Dementia, Brain Diseases, Central Nervous System Diseases
- Keywords
- cognitive decline, cognitive impairment, multi-domain lifestyle interventions, dementia, elderly
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,212 participants (actual)
- Lead sponsor
- National University of SingaporeUniversity, hospital or other
- Collaborators
- National Medical Research Council (NMRC), Singapore
- Study start
- 23 Aug 2021 (actual)
- Primary completion
- 1 Dec 2025 (actual)
- Study completion
- 29 Dec 2025 (actual)
- First posted
- 16 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study in Finland found that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. The SINGER study is a 2-year randomized controlled trial that aims to test the efficacy and safety of these lifestyle changes, including diet and cardiovascular risk factor management, cognitive and physical exercises, in delaying cognitive decline in older adults at risk of dementia.
Detailed description
Results from a population-based 2-year clinical trial, the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), demonstrated that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. Currently, no pharmacological treatment options that can rival these effects. Thus, there is an urgent need to test the generalizability, adaptability, and sustainability of these findings in Singaporean populations. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. Hence, the next step was to conduct a larger scale SINGER trial to determine the efficacy of these interventions in Singapore. If the interventions are found to be effective and safe with high applicability and scalability, the study will provide important clinical and public health implications to a rapidly increasing ageing population.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Structured Lifestyle Intervention | Experimental | Behavioral: Structured Lifestyle InterventionStructured lifestyle modification program developed for participants targeting diet, physical exercise, cognitive training, and social stimulation. |
| Self-Guided Intervention | Experimental | Behavioral: Self-Guided InterventionGeneral health information provided to participants. |
Who may qualify
- Ages
- 60 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age 60-80 years
- Able to understand English/Chinese
- Risk of dementia: Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) dementia risk score ≥6 indicating the presence of modifiable risk factors Modifiable lifestyle factors (fulfilling at least one of the following LIBRA index for diet, cognitive activity, physical activity)
- Cognitive performance at the mean level or slightly lower than expected for age (MoCA ≥18, ≤27)
- No plans to travel outside of Singapore for an extended period of time over the course of the study
Key exclusion criteria (7 listed)
- malignant diseases
- dementia
- major depression
- symptomatic cardiovascular disease
- revascularisation within 1 year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Structured Lifestyle InterventionAlso: SLIStructured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors. | Behavioural | Structured Lifestyle Intervention |
| Self-Guided InterventionAlso: SGIIn the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided. | Behavioural | Self-Guided Intervention |
Primary outcome
Global Cognition
Time frame: Up to 2 years
Global cognition measured using the modified Neuropsychological Test Battery (mNTB) that includes: Visual Paired Associates, Logical Memory Recall of the Wechsler Memory Scale-Revised, Rey Auditory Verbal Learning, Digit Span, Word and Category Fluency test, Trail Making Test, Letter Digit Substitution test.
23 secondary outcomes
Episodic Memory
Time frame: Up to 2 years
Executive Function
Time frame: Up to 2 years
Processing Speed
Time frame: Up to 2 years
Clinical Dementia Rating-Sum of Boxes (CDR-SB)
Time frame: Up to 2 years
Alzheimer's Disease Cooperative Study Activities of Daily Living-Mild Cognitive Impairment-Activities of Daily Living Inventory (ADCS-MCI-ADL)
Time frame: Up to 2 years
The Geriatric Depression Scale (GDS)
Time frame: Up to 2 years
Global Physical Activity Questionnaire (GPAQ)
Time frame: Up to 2 years
Prospective-Retrospective Memory Questionnaire
Time frame: Up to 2 years
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Up to 2 years
Leisure-Time Activities Questionnaire
Time frame: Up to 2 years
Physical Performance Test (PPT)
Time frame: Up to 2 years
Quality of Life Questionnaire (15D)
Time frame: Up to 2 years
36-Item Short Form Survey (SF-36)
Time frame: Up to 2 years
Resource Use Inventory (RUI)
Time frame: Up to 2 years
Height
Time frame: Up to 2 years
Weight
Time frame: Up to 2 years
Hip and waist circumference
Time frame: Up to 2 years
Changes in Blood Pressure
Time frame: Up to 2 years
Changes in Lipid Profile
Time frame: Up to 2 years
Changes in Glucose Regulation
Time frame: Up to 2 years
Neuroimaging
Time frame: Up to 2 years
Blood Biomarkers
Time frame: Up to 2 years
Retinal Imaging Markers
Time frame: Baseline only
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Background: PubMed 25771249Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.
- Background: PubMed 33748399Chew KA, Xu X, Siongco P, Villaraza S, Phua AKS, Wong ZX, Chung CY, Tang N, Chew E, Henry CJ, Koo E, Chen C. SINgapore GERiatric intervention study to reduce physical frailty and cognitive decline (SINGER)-pilot: A feasibility study. Alzheimers Dement (N Y). 2021 Mar 15;7(1):e12141. doi: 10.1002/trc2.12141. eCollection 2021.
- Derived from this study: PubMed 41943481Yap KH, Chen C, Chong EJY, Kandiah N, Kivipelto M, Lai MKP, Maier AB, Matchar DB, Phua AKS, Teo CKL, Xu X, Zhou HJ, Chen CPL. Baseline characteristics of the SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) multidomain dementia prevention randomized controlled trial and insights from the recruitment process. Alzheimers Dement. 2026 Apr;22(4):e71313. doi: 10.1002/alz.71313.
- Derived from this study: PubMed 40670782Ooi LQR, Orban C, Zhang S, Nichols TE, Tan TWK, Kong R, Marek S, Dosenbach NUF, Laumann TO, Gordon EM, Yap KH, Ji F, Chong JSX, Chen C, An L, Franzmeier N, Roemer-Cassiano SN, Hu Q, Ren J, Liu H, Chopra S, Cocuzza CV, Baker JT, Zhou JH, Bzdok D, Eickhoff SB, Holmes AJ, Yeo BTT; Alzheimer's Disease Neuroimaging Initiative. Longer scans boost prediction and cut costs in brain-wide association studies. Nature. 2025 Aug;644(8077):731-740. doi: 10.1038/s41586-025-09250-1. Epub 2025 Jul 16.
- Individual participant dataSharing planned: No. Interested collaborators may put in a request.
Related trials for Cognitive Impairment
Recruiting
Telehealth-Adapted Compensatory Training and Intervention for Cognition
MCI, Mild Cognitive Impairment
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Recruiting
Neurobehavioral Changes Following Spaceflight Stressors
Stressor, Individual, Alcohol Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christopher LH Chen, MD principal investigator
National University of Singapore
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Structured Lifestyle Intervention and Self-Guided Intervention in people with Cognitive Impairment and Alzheimer Disease, run by National University of Singapore at 3 sites in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Global Cognition (time frame: Up to 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05007353, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.